



PATENT APPLICATION NO.: 10/564,825  
ATTORNEY DOCKET NO.: 58767.000011

*SPW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/564,825 Confirmation No.: 3168  
Applicant : Pierre-Etienne Chabrier de LASSAUNIERE  
Filed : June 16, 2006  
Title : USE OF BOTULINUM TOXIN FOR PRODUCING DRUG FOR PREVENTING OR TREATING FINAL PHASE OF LUNG TROUBLES  
TC/Art Unit : 1645  
Examiner: : Vanessa L. Ford  
  
Docket No. : 58767.000011  
Customer No. : 21967

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08B (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

The attached documents were cited by the European Patent Office in the International Search Report dated February 11, 2005 of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited

references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

As this application was filed after June 30, 2003, copies of U.S. patents and/or U.S. patent application publications under 35 U.S.C. 371 cited on the attached Form PTO-SB/08B (modified), are not being provided as specified in 1276 O.G. 55 (5 August 2003).

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08B with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: Nov. 2, 2007

By:

  
Robert C. Lampe, III  
Registration No. 51,914

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)  
RCL/asc